Goldman Sachs
ABCL icon

Goldman Sachs’s AbCellera Biologics ABCL Stock Holding History

Goldman Sachs’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.85M Sell
235,127
-3,516,085
-94% -$17.2M ﹤0.01% 4746
2026
Q1 		$13.1M Sell
3,751,212
-593,273
-14% -$2.13M ﹤0.01% 2833
2025
Q4 		$14.9M Buy
4,344,485
+4,094,268
+1,636% +$18.3M ﹤0.01% 2672
2025
Q3 		$1.26M Buy
250,217
+31,492
+14% +$139K ﹤0.01% 4873
2025
Q2 		$750K Buy
218,725
+132,242
+153% +$329K ﹤0.01% 4902
2025
Q1 		$193K Sell
86,483
-213,330
-71% -$612K ﹤0.01% 5650
2024
Q4 		$878K Buy
299,813
+94,106
+46% +$262K ﹤0.01% 4903
2024
Q3 		$535K Buy
205,707
+109,939
+115% +$305K ﹤0.01% 5015
2024
Q2 		$283K Sell
95,768
-110,659
-54% -$419K ﹤0.01% 5132
2024
Q1 		$935K Sell
206,427
-394,814
-66% -$2.01M ﹤0.01% 4393
2023
Q4 		$3.43M Buy
601,241
+341,945
+132% +$1.58M ﹤0.01% 3485
2023
Q3 		$1.19M Sell
259,296
-160,981
-38% -$979K ﹤0.01% 4148
2023
Q2 		$2.71M Buy
420,277
+68,931
+20% +$470K ﹤0.01% 3634
2023
Q1 		$2.65M Sell
351,346
-113,530
-24% -$1.03M ﹤0.01% 3628
2022
Q4 		$4.71M Buy
464,876
+63,659
+16% +$735K ﹤0.01% 3219
2022
Q3 		$3.97M Buy
401,217
+166,730
+71% +$1.83M ﹤0.01% 3345
2022
Q2 		$2.5M Buy
234,487
+121,762
+108% +$1.03M ﹤0.01% 3853
2022
Q1 		$1.1M Sell
112,725
-22,724
-17% -$215K ﹤0.01% 4740
2021
Q4 		$1.94M Buy
135,449
+116,704
+623% +$1.77M ﹤0.01% 4282
2021
Q3 		$376K Sell
18,745
-12,310
-40% -$218K ﹤0.01% 5360
2021
Q2 		$683K Buy
31,055
+3,323
+12% +$91.6K ﹤0.01% 5023
2021
Q1 		$942K Buy
+27,732
New +$1.1M ﹤0.01% 4664

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Goldman Sachs's ABCL Position: Q2 2026 in Review

Goldman Sachs reduced its AbCellera Biologics (ABCL) stake by 94% in Q2 2026, selling an estimated $17.2M and leaving 235,127 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #4746.

Goldman Sachs first reported a position in ABCL in Q1 2021 and has held it in 22 quarters since. The position peaked at $14.9M in Q4 2025. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Goldman Sachs held 235,127 shares of AbCellera Biologics worth $1.85M as of Q2 2026.
  • Goldman Sachs sold 3,516,085 AbCellera Biologics shares in Q2 2026, an estimated $17.2M.
  • AbCellera Biologics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4746 holding.
  • Goldman Sachs first reported a position in AbCellera Biologics in Q1 2021 and has held it in 22 quarters since.
  • Goldman Sachs's AbCellera Biologics position peaked at $14.9M in Q4 2025.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.